IAVARONE, MASSIMO ALBERTO
 Distribuzione geografica
Continente #
EU - Europa 6.330
NA - Nord America 3.105
AS - Asia 1.653
SA - Sud America 77
AF - Africa 33
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 5
Totale 11.220
Nazione #
GB - Regno Unito 3.023
US - Stati Uniti d'America 2.999
CN - Cina 824
DE - Germania 810
IT - Italia 618
SE - Svezia 601
UA - Ucraina 276
FR - Francia 204
IN - India 198
IE - Irlanda 196
TR - Turchia 162
RU - Federazione Russa 161
KR - Corea 151
FI - Finlandia 115
EU - Europa 105
SG - Singapore 101
CA - Canada 100
HK - Hong Kong 92
PL - Polonia 89
NL - Olanda 85
CO - Colombia 54
DK - Danimarca 50
GR - Grecia 45
JP - Giappone 31
ID - Indonesia 29
TW - Taiwan 23
BE - Belgio 19
AU - Australia 13
BR - Brasile 13
CH - Svizzera 11
EG - Egitto 10
ES - Italia 10
SL - Sierra Leone 10
UZ - Uzbekistan 10
MM - Myanmar 5
MX - Messico 5
TH - Thailandia 5
VN - Vietnam 5
CL - Cile 4
MA - Marocco 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
SA - Arabia Saudita 4
AR - Argentina 3
CZ - Repubblica Ceca 3
GH - Ghana 3
IR - Iran 3
MY - Malesia 3
SC - Seychelles 3
AT - Austria 2
EE - Estonia 2
IL - Israele 2
LT - Lituania 2
PE - Perù 2
RO - Romania 2
AE - Emirati Arabi Uniti 1
BN - Brunei Darussalam 1
EC - Ecuador 1
ET - Etiopia 1
HU - Ungheria 1
IQ - Iraq 1
KE - Kenya 1
NG - Nigeria 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
SI - Slovenia 1
Totale 11.320
Città #
Southend 2.901
Chandler 437
Seattle 262
Jacksonville 237
Frankfurt am Main 231
Beijing 214
Milan 196
Princeton 190
Dublin 182
Wilmington 159
Ashburn 131
Nanjing 127
Ann Arbor 126
Mountain View 100
Redmond 95
Houston 89
Warsaw 84
Serra 80
Hong Kong 75
Dearborn 74
Toronto 71
Andover 67
Boardman 67
Bengaluru 66
Sakarya 64
Des Moines 62
Woodbridge 61
Fairfield 55
Bogotá 54
Singapore 51
Somerville 44
Shanghai 43
Jinan 42
Grafing 41
New York 38
Guangzhou 36
Redwood City 35
Shenyang 35
Helsinki 34
Athens 30
Berlin 28
Saint Petersburg 28
Changsha 26
Hanover 26
Turin 25
Phoenix 24
Nanchang 23
Tianjin 21
Bitonto 20
Mumbai 19
Brussels 18
Hangzhou 18
Zhengzhou 17
Hefei 16
Cambridge 15
Kunming 15
Rome 15
Hebei 14
Menlo Park 14
San Diego 13
Auburn Hills 12
Eitensheim 12
Sunnyvale 12
Jakarta 11
Roxbury 11
Taipei 10
Los Angeles 9
Montreal 9
Palaiseau 9
Columbus 8
Fremont 8
London 8
Ottawa 8
Taiyuan 8
Verona 8
Bologna 7
Falls Church 7
Kiez 7
Medford 7
Ningbo 7
Nuremberg 7
Padova 7
Pune 7
Taizhou 7
Bergamo 6
Chengdu 6
Chicago 6
Costa Mesa 6
Fuzhou 6
Gallo 6
Gussago 6
Jiaxing 6
Kaohsiung City 6
Lanzhou 6
São Paulo 6
Bari 5
Cairo 5
Central District 5
Haikou 5
Munich 5
Totale 7.678
Nome #
Multimodality treatment of hepatocellular carcinoma : How field practice complies with international recommendations 335
PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma 317
Hepatic fat - genetic risk score predicts hepatocellular carcinoma in HCV cirrhotic patients treated with DAAs 256
Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years 222
Experience Wwith Early Sorafenib Treatment with Mtor Inhibitors in Hepatocellular Carcinoma Recurring after Liver Transplantation 210
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 198
Serum expression of lectin reactive alphafetoprotein, des-gamma-carboxy prothrombin, Golgi protein-73 antigen and antibody, for the diagnosis of hepatocellular carcinoma 196
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 192
Assessing tumor angiogenesis : Increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells 186
Excellent 5-year overall survival in patients with HBV-related cirrhosis undergoing liver transplantation for hepatocellular carcinoma 183
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistant patients with HBeAg-negative chronic hepatitis B 180
High risk of renal impairment and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 171
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistano patients with HBeAg-negative chronic hepatitis B 168
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 168
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 165
Natural history of HCC developing in HBV-related cirrhotic patients undergoing antiviral treatment with nucleos(t)ide analogues 161
Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma 159
Very early add-on adefovir therapy in patients with sub-optimal virological response to lamivudine 157
Increased survival of patients with HCV-related cirrhosis with a long-term response to interferon therapy 156
A prospective study of peripheral blood alpha-fetoprotein messenger RNA in cirrhotic patients at risk of hepatocellular carcinoma 154
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 153
Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B 153
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine 152
Five years of sequential lam to lam_adv therapy suppresses HBV replication in most hbeag-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma 149
Recist versus easl criteria for the evaluation of HCC response to sorafenib 147
Six years of “on demand” LAM ± ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis 144
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudineresistant chronic hepatitis B 143
Add on Adefovir prevents the emergence of ADV resistance in Lamivudine-resistant patients : a 4-year study 143
Local circulation of VEGF is involved in collateral vessels development in cirrhotic patients with portal hypertension 142
Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis 142
Four years of Adefovir add-on in 145 lamivudine resistant patients with chronic hepatitis B : low risk of genotypic resistance to ADV and prevention of virologic breakthrough 140
Prevalence and natural history of portal vein thrombosis, evaluated by contrast enhanced ultrasonography (CEUS), in patients with hepatocellular carcinoma 139
Entecavir is an effective treatment for NUC-naive chronic hepatitis B patients in clinical practice : 48-week data from a large multicenter cohort study 137
Low risk of hepatitis B reactivation in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 137
Transient elastography (TE) accurately predicts liver fibrosis stage in patients with chronic hepatitis B 137
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 137
Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma 136
Effectiveness of entecavir for the treatment of nuc-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 135
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices : a 12-year prospective cohort study 135
The clinical and pathogenetic significance of estrogen receptor-beta expression in chronic liver diseases and liver carcinoma 133
Global Antiviral Journal “Bridging the Sciencies, HIV, HBV, HCV and Emerging Viruses” 131
Prospective validation of immunohistological stain for glypican-3 (GPC-3) in the early diagnosis of hepatocellular carcinoma 129
Effectiveness of entecavir for the treatment of NUC-naïve chronic hepatitis B patients : A large multicenter cohort study in clinical practice 128
Low risk of hepatitis B reactivatioin in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 128
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation 128
Field practice with sorafenib in advanced HCC : effectiveness confirmed, reduced tolerability compared to registration trials 125
Prospective study of dysplastic nodules in cirrhosis : correlation with CT vascular pattern, histology and development of hepatocellular carcinoma 124
Six years of on demand LAM +/- ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with hbeag-negative cirrhosis 123
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 123
Chemoembolization with epirubicin drug eluting beads to treat early and intermediate hepatocellular carcinoma 122
Prospective validation of AASLD guidelines for the early diagnosis of hepatocellular carcinoma in cirrhotic patients 122
Prospective study of dysplastic nodes in cirrhotic patients : correlation with CT vascular pattern 122
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 122
The natural history of hepatic macroregenerative nodules developing in cirrhotic patients during surveillance with ultrasound (US) 121
Prospective validation of immunohistological stain for glypican-3 (GPC-3) in the early diagnosis of hepatocellular carcinoma 118
The natural history of macroregenerative nodules prospectively detected in cirrhotic patients under surveillance 114
The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin 113
Low resistance to adefovir combined with lamivudine : a 3-year study of 145 lamivudine-resistant hepatitis B patients 113
TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma 113
Prospective evaluation of staging systems for hepatocellular carcinoma detected during surveillance of cirrhotic patients 112
Prospective validation of AASLD guidelines for the early diagnosis of hepatocellular carcinoma in cirrhotic patients 109
Hepatocellular carcinoma in patients with compensated HCV-related cirrhosis responding to interferon : A 5-year follow-up study 106
Congenital Hepatic Fibrosis as a Cause of Recurrent Cholangitis: A Case Report and Review of the Literature 106
Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib 105
Progressive decline of HBsAg titers in longterm virological responders to nucleos(t)ide analogue therapy for chronic hepatitis B 103
Prospective study of dysplastic nodules in cirrhosis : correlation with CT vascular pattern, histology and development of hepatocellular carcinoma 102
Low risk of hepatocellular carcinoma recurrence after liver transplantation : a 3-year follow-up study in 78 patients with chronic hepatitis B 101
Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics 100
The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma 99
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib 98
Maintained HBV suppression in lamivudine-resistant patients treated with adefovir and lamivudine combination : A 4- year cohort study in 63 patients 96
Six years of "on demand" LAM plus ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis 95
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B 95
Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL) : a randomised, controlled, phase 2b/3 trial 95
High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis 93
Progressive decline of HBsAg titers in long-term virological responders to nucleos(t)ide analogue therapy for chronic hepatitis B 91
Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis 91
Sorafenib treatment of advanced hepatocellular carcinoma : a post-marketing study 87
Cholangiocarcinoma in Cirrhosis : Value of Hepatocyte Specific Magnetic Resonance Imaging 83
A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene 79
Role of antiviral treatment for HCC prevention 77
Hepatitis B-related hepatocellular carcinoma 75
Sorafenib in Clinical Practice: Evidence-Based Use or Abuse? Reply 71
Field-practice study of sorafenib therapy for hepatocellular carcinoma : a prospective multicenter study in Italy 69
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma 69
HBV-related HCC, clinical issues and therapy 63
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound 62
Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19 60
Interventional radiology image-guided locoregional therapies (Lrts) and immunotherapy for the treatment of hcc 58
An unprecedented challenge: The north italian gastroenterologist response to COVID-19 47
A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration 44
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis 42
HBV infection and hepatocellular carcinoma 40
Clinical Impact of a Protocol Involving Cone-Beam CT (CBCT), Fusion Imaging and Ablation Volume Prediction in Percutaneous Image-Guided Microwave Ablation in Patients with Hepatocellular Carcinoma Unsuitable for Standard Ultrasound (US) Guidance 24
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 17
null 3
Totale 11.954
Categoria #
all - tutte 27.756
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.756


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201988 0 0 0 0 0 0 0 0 0 0 0 88
2019/20201.408 195 51 63 112 60 163 142 145 235 127 80 35
2020/20211.556 76 109 134 20 123 97 91 108 182 89 379 148
2021/20221.328 103 78 47 96 78 69 110 127 144 197 56 223
2022/20231.539 177 157 119 177 183 292 33 99 177 24 78 23
2023/20241.075 39 71 52 64 306 78 81 76 65 75 119 49
Totale 11.954